# Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

> **NCT01114282** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** velcade
- **DRUG:** Pralatrexate

## Key facts

- **NCT ID:** NCT01114282
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114282, "Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01114282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*